Pharma BD Deal Intelligence
A $2.6B combination of Patheon and DSM Pharmaceutical Products that became a $7.2B exit for Thermo Fisher just 3.5 years later. The CDMO roll-up paired drug product manufacturing with API/biologics under one "OneSource" offering, IPO'd in 2016, and nearly tripled in value before being acquired in 2017.
JLL executives believed the fragmented contract manufacturing industry was ripe for a roll-up at a time when pharma was looking for partners with a spectrum of…
DSM characterized the move as a key step in the strategic transformation of its Pharma activities into partnerships, monetizing DPP while retaining 49% upside…
JLL Partners closed the merger forming DPx Holdings, calling it a transformative platform for CDMO consolidation.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
JLL Partners and Royal DSM created DPx Holdings BV (later Patheon NV) by combining DSM Pharmaceutical Products and Patheon in $2.6B transaction; Patheon enterprise value ~$1.98B at $9.32/share.
Assessment window: 5yr post-close.
$2.0B Combined NewCo pro-forma 2014 sales (USD)
Contract Development & Manufacturing Organizations (CDMOs) provide outsourced drug development, API manufacturing, and finished dosage production for pharma and biotech sponsors. Demand is driven by sponsors seeking to convert fixed manufacturing costs into variable spend, access specialized capabilities (sterile fill-finish, biologics, HPAPI), and accelerate time-to-clinic. The sector is highly fragmented and capital-intensive, rewarding scale, breadth of dosage form expertise, and global regulatory footprint.
In 2013 the CDMO market was fragmented across thousands of small and mid-cap players, with Lonza, Catalent, Patheon, and Boehringer Ingelheim's contract business as recognized scale leaders. By combining Patheon's North American oral-solids and sterile dosage footprint with DSM Pharmaceutical Products' API and biologics capabilities (including DSM's Brisbane biologics site and Greenville API plant), DPx Holdings BV created a roughly $2B revenue end-to-end CDMO with 23 facilities and ~8,300 employees, positioned to compete head-to-head with Lonza and Catalent across small molecules, sterile injectables, APIs, and biologics. JLL Partners contributed $489M cash for 51% ownership while DSM contributed DPP (valued at $670M) plus took a $200M seller note for 49%; Patheon was acquired at $9.32/share, a 64% premium, for ~$1.95B enterprise value. Strategically the deal validated JLL's roll-up thesis that fragmented CDMOs would consolidate as sponsors sought partners with full-service breadth and global reach. The combined entity (later renamed Patheon NV) IPO'd in 2016 and was acquired by Thermo Fisher in 2017 for $7.2B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products (this deal) | 2013 | $2.6B | 90 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
← Browse all deals · How we score deals
More: 2013 deals · Other deals